

GUIDELINES FOR THE E-POSTER EXHIBIT

Electronic posters of original research papers done by PDS members/residents/conference attendees will be displayed for viewing in widescreens during the PDS 49th Annual Convention.

Submission of abstracts will be done through the official website of the PDS 49th Annual Convention at <https://pdsconvention2026.com/> after successful registration for the meeting has been made.

The Research Committee will screen the abstracts for eligibility for inclusion in exhibit. Once accepted, authors will receive a letter of acceptance through their email.

I. OBJECTIVE

To promote the dissemination of original research papers done by PDS members and residents.

II. ELIGIBILITY OF ENTRIES

1. Any original research by a PDS resident or member may be submitted, such as:
 - a. Experimental study
 - b. Non-experimental study
 - c. Case report/case series
2. Experimental studies, and non-experimental studies should have been approved by an Institutional Review Board (IRB).
3. Case reports and case series must have obtained informed consent from the patients if patient's photographs and information are not de-identified.
4. The following manuscripts are eligible:
 - a. Manuscripts that were submitted but did not qualify for the current year's Residents' Research Forum and Case Report Contest oral presentation
 - b. Manuscripts that have been presented in any national or international scientific meeting or conference.
5. Industry-sponsored or -initiated papers remain eligible, provided the primary author is a PDS resident or member, and the sponsorship/commercial support is disclosed.
6. The following are not eligible for the e-Poster Exhibit:
 - a. Manuscripts that have been published in any medical journal

III. REQUIREMENTS FOR SUBMISSION

1. The following are the required documents for electronic submission:
 - a. Patient's duly accomplished informed consent for case reports / case series
 - b. Copy of IRB approval letter/s for experimental / non-experimental studies
 - c. E-Poster of the manuscript (in PDF format)
2. Submission of the abstract indicates that all authors agree to the content of the paper, and to the submission of the e-posters.
3. The Research Committee reserves the right to reassign any submission to another category if they determine it is more applicable to the content of the abstract.
4. All accepted submissions will be included in the e-book of Abstracts.

IV. PREPARATION FOR EPOSTER SUBMISSION

1. The title should be concise and indicative of the content of the paper. It should not exceed 30 words, should not contain abbreviations, and only the first letter of the first word and proper nouns are capitalized.
2. Categories:

Table 1. E-Poster Categories

E-POSTER CATEGORIES	
• Acne • Aesthetic/Cosmetic Dermatology • Aging/Geriatrics • Autoimmune Disorders and Connective Tissue Diseases • Basic Science • Community Dermatology • Contact Dermatitis: Allergic & Irritant • Dermatopathology • Dermatologic Surgery • Diagnostic Techniques/Immunostaining • Digital/Electronic Technology (ie dermoscopy, digital imaging technology) • Disorders of the Subcutaneous Tissue • Eczema • Epidemiology & Health Services Administration • Genodermatoses • Hair & Nail Disorders	• Immunodermatology & Blistering Disorders • Infections • Internal Medicine Dermatology • Papulosquamous Disorders • Pediatric Dermatology • Pharmacology • Photobiology, Phototherapy & Photosensitivity Diseases • Pigmented lesions, disorders & pigmentary changes • Psychocutaneous and neurocutaneous Diseases • Surgery (laser, cosmetic, dermatologic) • Telemedicine • Tropical Dermatology • Tumors • Vascular Anomalies/Disorders • Wound Healing & Ulcers • Regenerative medicine

3. The abstract must be written in English, structured, and limited to 250 words. It should emphasize new and important aspects of the study or observations, as well as accurately reflect the content of the article. Clinical trial abstracts should include items that the CONSORT group has identified as essential.

For experimental and non-experimental studies, the abstract should be structured and organized as follows:

- a. Background: What is the major problem that prompted the study?
- b. Objective/s: What is the purpose of the study?
- c. Methods: How was the study done?
- d. Results: What are the most important findings?
- e. Conclusion: What is the single most important conclusion?

For case reports, the abstract should be structured and organized as follows:

- a. Introduction: Why is your case unique? Why can your findings be associated with a particular intervention?
- b. Case Report: What are the patient's main concerns and important clinical findings?
- c. Discussion: Explain the rationale for reporting your case. What is your most important conclusion?

4. **Keywords:**

Provide 3-5 keywords or brief phrases that will assist the indexers in cross-indexing your article and that may be published with the abstract. Use terms from the Medical Subject Headings (MeSH) list of Index Medicus. If MeSH terms are not available for recently introduced terms, present terms may be used.

5. **Conflict of Interest:**

Potential study interpretation conflicts may include, but are not limited to, the following:

- Some or all of the research planning and conduct were carried out by the pharmaceutical company / commercial organization with a vested interest in the product being studied.
- Some or all of the data that were used in the study were provided by a pharmaceutical company / organization with a vested interest in the product being studied.
- Some or all of the data analysis and results interpretation was conducted by a pharmaceutical company / organization with a vested interest in the product being studied.

6. **Commercial Funding:**

Financial competing interests may include, but are not limited to, the following:

- Receiving reimbursements, fees, funding, or salary from a/n pharmaceutical company / commercial organization that may in any way gain or lose financially from the publication of the article, either now or in the future.
- Ownership by the author or a first-degree relative (e.g. sibling, parent, spouse) or a company that sells a product related to the subject matter of the manuscript.

The following situations are not considered financial competing interests:

- The donation of topical or oral medications, biologics, devices, and equipment from a pharmaceutical company
- Lease / loan of machines (e.g. light, laser and energy based machines) from pharmaceutical company
- Financial support for study procedures required by guidelines in the use of a pharmaceutical agent by a pharmaceutical company
- The provision of an educational grant from a pharmaceutical company / commercial organization.

7. Trade names for drugs, devices and/or instrumentation (e.g. mexameter, evidence based devices, biologics, soft tissue fillers), should not be used. Any medications, substances or devices should be identified by their scientific or generic name only. To distinguish a formulation or device, use "generic name or description, [Manufacturer's name].

V. E-POSTER PREPARATION

1. Please see below the technical guidelines for the e-poster.

	E-POSTER SPECIFICATIONS
Presentation program	Microsoft Office PowerPoint or Keynote
Slide ratio/orientation	width: 11.25 in (28.575 cm) height: 20 in (50.8 cm)
Resolution	1080 x 1920
Font style	Times New Roman, Arial, Calibri, or Tahoma
Font size (minimum)	Title: 24 body: 18 Description/explanation of figures: 14
Graphs and diagrams	Minimum line width of 2 mm
Maximum no. of slides	1
File format to be submitted	PDF format

2. Use background and text colors which provide a high level of contrast, e.g. white or yellow text against a darkblue or black background.
 3. The e-poster should include the poster title, names of authors, disclosure of commercial support, if any, and major references only (maximum of 5).
 4. The e-poster should have the following headings:
Case Reports; *Abstract, Introduction, Case Report, Discussion, References*
Non-experimental and experimental studies: *Abstract, Introduction, Methods, Results, Discussion, References*
 5. Conflicts of interest and commercial funding should be disclosed, or stated as none, through a statement on one of their slides.
 6. Description, explanations, or text below figures should be *italized* and the font size smaller than the font size of the body of the poster.
 7. Patient's photographs and personal information (i.e. patient's pedigree or demographics) should be de-identified, unless a written informed consent has been obtained from the patient, allowing his/her photos not to be de-identified.
 8. The source of photographs, tables, and illustrations must be declared if they are not the property of the presenter.
 9. Trade names for drugs, devices and/or instrumentation including lasers, should appear only once. Include the "generic name or description, [Manufacturer's name]". Product or industry logos should not be included in the poster.
-

APPENDIX I
Cover Letter

COVER LETTER

Date:

To: PDS Research Committee

From:

I. CATEGORY:

☐ Eposter, Experimental study

☐ Eposter, Non-experimental

☐ Eposter, Case Report Contest

II. TITLE:

III. NAMES OF AUTHORS (in order of authorship, with the name of the presenter in **BOLD** letters):

- 1.
- 2.
- 3.
- 4.

I certify that (mandatory):

1. The study was conducted according to the IRB-approved protocol and protocol amendments.
2. The manuscript has been seen and approved by all authors. Authors approve the entry of the paper in the Eposter exhibit.
3. The manuscript has not been accepted or published in any medical journal.
4. The authors agree to include the abstract in the PDS Research Inventory.¹
5. I have disclosed all conflicts of interest and source of funding in the manuscript.
6. The institution and the authors of the paper are willing to abide by the rules and regulations of the forum, and the decision of the forum organizers.
7. **All authors give their consent to have their abstract published in the e-Book of Abstracts.²**

Signature over Printed Name (Author 1), Date

Signature over Printed Name (Author 2), Date

Signature over Printed Name (Author 3), Date

Signature over Printed Name (Author 4), Date

¹ The PDS Research Inventory is a repository of all research submissions archived in the PDS Library and preserved indefinitely for reference purposes. The Research Inventory serves as a comprehensive record of all research conducted by PDS members and affiliated institutions.

² The e-Book of Abstracts will be published as part of the supplemental issue of the Journal of the Philippine Dermatological Society. This issue will be indexed in online databases such as HERDIN and WPRIM. Retraction of submitted articles is not allowed. In case of retraction, the author should abide by the retraction policy of JPDS.

APPENDIX II
Conflict of Interest Form

CONFLICT OF INTEREST DISCLOSURE STATEMENT

Authors are responsible for disclosing all financial and personal relationships between themselves and others (e.g. pharmaceutical companies) that might be perceived by others as a source of bias.

Papers with financial competing interests or potential study interpretation conflicts will not be eligible to compete in the Annual Residents' Research forum or Case Report Contest

Submit only one Conflict of Interest (COI) form if all authors have the same COI to declare. If not, the author/s that have different declarations should accomplish and submit their individual COI forms.

I/we have submitted a manuscript for possible presentation in the Philippine Dermatological Society's:

☐ PDS Members' Forum

☐ Eposter

Title of Manuscript: _____

To the best of my/our knowledge, the following are true of the submitted manuscript:

1. Neither I/we, nor the data reported in the manuscript have financial competing interests¹ from any pharmaceutical company or other commercial interest, except as described below.
2. The data reported in the manuscript does not have any potential study interpretation

conflicts.² Please use the space below to describe any possible exceptions:

I/we, the undersigned, have completed this form to the best of my/our knowledge.

Signature over Printed Name (Author 1), Date

Signature over Printed Name (Author 2), Date

Signature over Printed Name (Author 3), Date

Signature over Printed Name (Author 4), Date

1 Financial competing interests may include, but are not limited to, the following:

- a. Receiving reimbursements, fees, funding, or salary from a/n pharmaceutical company/ commercial organization that may in any way gain or lose financially from the publication of the article, either now or in the future.
- b. Ownership by the author or a first-degree relative (e.g. sibling, parent, spouse) of a company that sells a product related to the subject matter of the manuscript.

The following situations are not considered financial competing interests:

- a. The donation of topical or oral medications, biologics, devices, and equipment from a pharmaceutical company.
- b. Lease/loan of machines (e.g. light, laser and energy based machines) from pharmaceutical company.
- c. Financial support for study procedures required by guidelines in the use of a pharmaceutical agent by a pharmaceutical company.
- d. The provision of an educational grant from a pharmaceutical company/commercial organization.

2 Potential study interpretation conflicts may include, but are not limited to, the following:

- a. Some or all of the research planning and conduct were carried out by the pharmaceutical company/commercial organization with a vested interest in the product being studied.
- b. Some or all of the data that were used in the study were provided by a pharmaceutical company/organization with a vested interest in the product being studied.
- c. Some or all of the data analysis and results interpretation was conducted by a pharmaceutical company/organization with a vested interest in the product being studied.

APPENDIX III

Abstract Form

CATEGORY: Eposter

SUBJECT CATEGORY: (Refer to Table 1 Categories)

TITLE:

(Center aligned, Calibri size 12 font, bold, left aligned only first letter of first word and proper nouns should be capitalized; not more than 30 words; concise and indicative of the content of the paper; not containing abbreviations)

AUTHORS:

First Name, Middle Initial, Last Name

(Calibri, size 10 font; Italics; Affiliations numbered in superscript (eg. Phoebe D. Santos, MD, FPD¹)

AFFILIATIONS

highest earned academic position or degree, institutional affiliation

(Calibri, size 10 font; Italics; Department, Institution, City/Town, Country)

(eg. ¹ Associate Professor, University of the East Ramon Magsaysay Memorial Medical Center)

CORRESPONDING AUTHOR

Complete name:

Email address:

(Calibri, size 10 font)

ABSTRACT

1. Font style: Calibri
2. Font size: 12
3. Alignment: justified
4. No. of words: maximum of 250 words
5. Abstract should be structured, with the following subheadings:
For experimental and non-experimental studies: *Background, Objective/s, Methods, Results, Conclusion*
For case reports: *Introduction, Case Report, Conclusion*
6. The subheadings must be underlined and in bold letters

Keywords:

- Provide 3-5 keywords
- Use terms from the Medical Subject Headings (MeSH) list of Index Medicus. If MeSH terms are not available for recently introduced terms, present terms may be used.
- should be written as: **Keywords:** [3-5 words]

Commercial funding: if none, please write N/A

Conflict of interest: if none, please write N/A

The abstracts of manuscripts submitted as entries for the Annual Research Forum, Case Report Contest, Members' Forum and E-poster exhibit will be compiled in a book of abstracts that are given to all the participants or delegates of the PDS Annual Convention. By signing below, you agree to the inclusion of this abstract in the E-book of Abstracts.

[Name and signature of primary or submitting author]